{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:08:54Z","timestamp":1792638534499,"version":"4.5.0"},"reference-count":214,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82305001"],"award-info":[{"award-number":["82305001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2025C02182"],"award-info":[{"award-number":["2025C02182"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3503900"],"award-info":[{"award-number":["2023YFC3503900"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LQ24H280011"],"award-info":[{"award-number":["LQ24H280011"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.phrs.2025.108066","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T17:30:17Z","timestamp":1765560617000},"page":"108066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Antibody-drug conjugates: A new twist to overcome EGFR-TKIs resistance in non-small cell lung cancer"],"prefix":"10.1016","volume":"223","author":[{"given":"Shengqian","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengtao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusha","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jizhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7586-9067","authenticated-orcid":false,"given":"Guoyin","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10299","key":"10.1016\/j.phrs.2025.108066_bib1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer","volume":"398","author":"Thai","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.phrs.2025.108066_bib2","first-page":"409","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA a cancer journal clinicians"},{"issue":"9","key":"10.1016\/j.phrs.2025.108066_bib3","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/JTO.0000000000000663","article-title":"Introduction to The 2015 world health organization classification of tumors of the lung, pleura, thymus, and heart","volume":"10","author":"Travis","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.phrs.2025.108066_bib4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/resp.13869","article-title":"Exercise training as part of lung cancer therapy","volume":"25","author":"Cavalheri","year":"2020","journal-title":"Respirology"},{"issue":"2","key":"10.1016\/j.phrs.2025.108066_bib5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/thoraxjnl-2015-207697","article-title":"Long-term impact of developing a postoperative pulmonary complication after lung surgery","volume":"71","author":"Lugg","year":"2016","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.phrs.2025.108066_bib6","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.chest.2023.11.042","article-title":"Recurrence-Free Survival in Patients With Surgically Resected Non-Small Cell Lung Cancer: A Systematic Literature Review and Meta-Analysis","volume":"165","author":"Rajaram","year":"2024","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.phrs.2025.108066_bib7","doi-asserted-by":"crossref","first-page":"340","DOI":"10.6004\/jnccn.2023.0020","article-title":"NCCN Guidelines\u00ae Insights: Non-Small Cell Lung Cancer, Version 2.2023","volume":"21","author":"Ettinger","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"2","key":"10.1016\/j.phrs.2025.108066_bib8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1470-2045(21)00630-6","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188645","article-title":"Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer","volume":"1877","author":"Tian","year":"2022","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"issue":"15","key":"10.1016\/j.phrs.2025.108066_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120858","article-title":"Personalized therapy for lung cancer: striking a moving target","volume":"3","author":"Pakkala","year":"2018","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.phrs.2025.108066_bib11","first-page":"387","article-title":"Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management","volume":"75","author":"Borgeaud","year":"2025","journal-title":"CA a cancer journal clinicians"},{"key":"10.1016\/j.phrs.2025.108066_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105583","article-title":"EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research","volume":"167","author":"Dong","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"8","key":"10.1016\/j.phrs.2025.108066_bib13","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin. Proc."},{"issue":"11","key":"10.1016\/j.phrs.2025.108066_bib14","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in NSCLC","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.phrs.2025.108066_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1252652","article-title":"A narrative review of antibody-drug conjugates in EGFR-mutated non-small cell lung cancer","volume":"13","author":"Hsu","year":"2023","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2025.108066_bib17","doi-asserted-by":"crossref","first-page":"936","DOI":"10.21037\/tlcr-24-100","article-title":"Antibody-drug conjugate development: opening windows for EGFR-mutant EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancers?","volume":"13","author":"Hida","year":"2024","journal-title":"Transl. lung Cancer Res."},{"issue":"3","key":"10.1016\/j.phrs.2025.108066_bib18","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1021\/acs.jmedchem.9b01566","article-title":"Discovery of potent and selective epidermal growth factor receptor (EGFR) bifunctional small-molecule degraders","volume":"63","author":"Cheng","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2025.108066_bib19","article-title":"Olaparib combined with dacomitinib in osimertinib-resistant brain and leptomeningeal metastases from non-small cell lung cancer: a case report and systematic review","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41591-018-0264-7","article-title":"Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer","volume":"25","author":"Shah","year":"2019","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.phrs.2025.108066_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/jpm15020050","article-title":"Targeting metabolic vulnerabilities to combat drug resistance in cancer therapy","volume":"15","author":"Khan","year":"2025","journal-title":"J. Pers. Med."},{"issue":"27","key":"10.1016\/j.phrs.2025.108066_bib22","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.phrs.2025.108066_bib23","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.phrs.2025.108066_bib24","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an Irreversible EGFR TKI, Overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"issue":"44","key":"10.1016\/j.phrs.2025.108066_bib25","article-title":"Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report","volume":"100","author":"Wang","year":"2021","journal-title":"Med. (Baltim. )"},{"issue":"48","key":"10.1016\/j.phrs.2025.108066_bib26","article-title":"Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials","volume":"101","author":"Li","year":"2022","journal-title":"Med. (Baltim. )"},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41698-021-00231-x","article-title":"Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC","volume":"5","author":"Peters","year":"2021","journal-title":"NPJ Precis. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib28","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib29","doi-asserted-by":"crossref","first-page":"8983","DOI":"10.1038\/s41598-022-12995-8","article-title":"AXL\/CDCP1\/SRC axis confers acquired resistance to osimertinib in lung cancer","volume":"12","author":"Murakami","year":"2022","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.phrs.2025.108066_bib30","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.112.197756","article-title":"Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker","volume":"343","author":"Solca","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2025.108066_bib31","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jtho.2019.12.126","article-title":"Afatinib for the Treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases","volume":"15","author":"Yang","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.phrs.2025.108066_bib32","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1073\/pnas.0808930106","article-title":"HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy","volume":"106","author":"Perera","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.phrs.2025.108066_bib33","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.phrs.2025.108066_bib34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s40265-020-01441-6","article-title":"Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR-activating mutations","volume":"81","author":"Mok","year":"2021","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12943-018-0778-0","article-title":"Third generation EGFR TKIs: current data and future directions","volume":"17","author":"Tan","year":"2018","journal-title":"Mol. Cancer"},{"issue":"18","key":"10.1016\/j.phrs.2025.108066_bib36","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in Resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.phrs.2025.108066_bib37","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.1158\/0008-5472.CAN-21-0556","article-title":"Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR tyrosine kinase inhibitor, osimertinib","volume":"81","author":"Zhu","year":"2021","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.phrs.2025.108066_bib38","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1158\/1078-0432.CCR-22-0341","article-title":"An ascendant challenge: central nervous system metastases in ALK+ Lung Cancers","volume":"28","author":"Murciano-Goroff","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2025.108066_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.750031","article-title":"Experimental study of almonertinib crossing the blood-brain barrier in EGFR-Mutant NSCLC brain metastasis and spinal cord metastasis models","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.phrs.2025.108066_bib40","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.jtho.2020.06.018","article-title":"Osimertinib improves overall survival in patients With EGFR-Mutated NSCLC with leptomeningeal metastases regardless of T790M Mutational Status","volume":"15","author":"Lee","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.phrs.2025.108066_bib41","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.jtho.2020.09.001","article-title":"Safety, Efficacy, and pharmacokinetics of almonertinib (HS-10296) in pretreated patients with EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial","volume":"15","author":"Yang","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2025.108066_bib42","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jtho.2021.10.024","article-title":"Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: updated post-national medical products administration approval results from the APOLLO registrational trial","volume":"17","author":"Lu","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"17","key":"10.1016\/j.phrs.2025.108066_bib43","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-14-2789","article-title":"EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors","volume":"21","author":"Ercan","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2025.108066_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116074","article-title":"Identification of novel aminopyrimidine derivatives for the treatment of mutant NSCLC","volume":"265","author":"Hu","year":"2024","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.phrs.2025.108066_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116590","article-title":"Discovery of new cyclopropane sulfonamide derivatives as EGFR inhibitors to overcome C797S-mediated resistance and EGFR double mutation","volume":"275","author":"Yao","year":"2024","journal-title":"Eur. J. Med Chem."},{"issue":"4","key":"10.1016\/j.phrs.2025.108066_bib46","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jtho.2016.12.014","article-title":"Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer","volume":"12","author":"Castellanos","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.phrs.2025.108066_bib47","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920937902","article-title":"Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies","volume":"12","author":"Walsh","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"12","key":"10.1016\/j.phrs.2025.108066_bib48","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","article-title":"Non-genetic mechanisms of therapeutic resistance in cancer","volume":"20","author":"Marine","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.phrs.2025.108066_bib49","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.phrs.2025.108066_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25115917","article-title":"Targeted Therapies for EGFR Exon 20 insertion mutation in non-small-cell lung cancer","volume":"25","author":"Seo","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2025.108066_bib51","article-title":"Receptor tyrosine kinase fusion-mediated resistance to EGFR TKI in EGFR-Mutant NSCLC: a multi-center analysis and literature review","volume":"20","author":"Yang","year":"2024"},{"issue":"4","key":"10.1016\/j.phrs.2025.108066_bib52","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.3892\/etm.2017.4847","article-title":"Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway","volume":"14","author":"Ma","year":"2017","journal-title":"Exp. Ther. Med."},{"issue":"4","key":"10.1016\/j.phrs.2025.108066_bib53","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s13402-013-0133-9","article-title":"Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer","volume":"36","author":"Peled","year":"2013","journal-title":"Cell Oncology (Dordr"},{"issue":"51","key":"10.1016\/j.phrs.2025.108066_bib54","doi-asserted-by":"crossref","first-page":"88529","DOI":"10.18632\/oncotarget.19874","article-title":"Plasma microRNA alterations between EGFR-activating mutational NSCLC patients with and without primary resistance to TKI","volume":"8","author":"Ma","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.phrs.2025.108066_bib55","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1158\/1078-0432.CCR-18-3829","article-title":"On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation","volume":"25","author":"Brown","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.phrs.2025.108066_bib56","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.32604\/or.2025.059311","article-title":"Multimodal omics analysis of the EGFR signaling pathway in non-small cell lung cancer and emerging therapeutic strategies","volume":"33","author":"Li","year":"2025","journal-title":"Oncol. Res."},{"issue":"17","key":"10.1016\/j.phrs.2025.108066_bib57","doi-asserted-by":"crossref","first-page":"935","DOI":"10.21037\/atm-22-3850","article-title":"Association between EGFR gene mutant protein expression and T790M mutation after first-generation EGFR-TKI treatment resistance: a retrospective, single-arm clinical study","volume":"10","author":"Zhang","year":"2022","journal-title":"Ann. Transl. Med."},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib58","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1186\/s12885-022-09869-7","article-title":"Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer","volume":"22","author":"Matsumoto","year":"2022","journal-title":"BMC Cancer"},{"issue":"0","key":"10.1016\/j.phrs.2025.108066_bib59","article-title":"Real-world clinical practice and outcomes in Peruvian patients with advanced EGFR T790M mutation positive NSCLC: A multicenter analysis","volume":"43","author":"Marco","year":"2025"},{"key":"10.1016\/j.phrs.2025.108066_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107714","article-title":"Design, synthesis and bioevaluation of dual EGFR-PI3K\u03b1 inhibitors for potential treatment of NSCLC","volume":"151","author":"Wang","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phrs.2025.108066_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113984","article-title":"Discovery of highly potent and selective EGFR(T790M\/L858R) TKIs against NSCLC based on molecular dynamic simulation","volume":"228","author":"Yang","year":"2022","journal-title":"Eur. J. Med Chem."},{"issue":"6","key":"10.1016\/j.phrs.2025.108066_bib62","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1158\/1078-0432.CCR-21-2595","article-title":"A Novel Third-generation EGFR tyrosine kinase inhibitor abivertinib for EGFR T790M-mutant non-small cell lung cancer: a multicenter phase i\/ii study","volume":"28","author":"Zhou","year":"2022","journal-title":"Clinical cancer research official journal American Association Cancer Research"},{"issue":"8","key":"10.1016\/j.phrs.2025.108066_bib63","doi-asserted-by":"crossref","first-page":"viii740","DOI":"10.1093\/annonc\/mdy424.063","article-title":"Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study","volume":"29","author":"Ramalingam","year":"2018","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib64","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.phrs.2025.108066_bib65","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/j.jtho.2019.07.016","article-title":"EGFR-mutated lung cancers resistant to osimertinib through EGFR C797S respond to first-generation reversible egfr inhibitors but eventually acquire EGFR T790M\/C797S in preclinical models and clinical samples","volume":"14","author":"Rangachari","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib66","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41698-024-00542-9","article-title":"A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer","volume":"8","author":"Suzuki","year":"2024","journal-title":"NPJ Precis. Oncol."},{"issue":"7","key":"10.1016\/j.phrs.2025.108066_bib67","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/jjco\/hyad052","article-title":"Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance","volume":"53","author":"Araki","year":"2023","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.phrs.2025.108066_bib68","article-title":"Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report","volume":"4","author":"Enrico","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"issue":"_1","key":"10.1016\/j.phrs.2025.108066_bib69","doi-asserted-by":"crossref","first-page":"i28","DOI":"10.1093\/annonc\/mdx705","article-title":"Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer","volume":"29","author":"Ricordel","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2025.108066_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114643","article-title":"Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry","volume":"190","author":"Scalvini","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib71","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12964-023-01082-8","article-title":"Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer","volume":"21","author":"Li","year":"2023","journal-title":"Cell communication signaling CCS"},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib72","article-title":"Clonal evolution and heterogeneity of osimertinib acquired resistance mechanisms in EGFR Mutant Lung Cancer","volume":"1","author":"Roper","year":"2020","journal-title":"Cell Rep. Med."},{"issue":"11","key":"10.1016\/j.phrs.2025.108066_bib73","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1002\/cncr.32810","article-title":"Overcoming resistance to osimertinib in non-small cell lung cancer: Hopes, doubts, and in-between","volume":"126","author":"Passaro","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.phrs.2025.108066_bib74","article-title":"Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors","volume":"14","author":"Yu-Ra","year":"2022"},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib75","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jtho.2019.10.003","article-title":"A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients","volume":"15","author":"Scagliotti","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib76","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41571-021-00558-1","article-title":"EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment","volume":"19","author":"Friedlaender","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2025.108066_bib77","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib78","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/1759-7714.13255","article-title":"Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation","volume":"11","author":"Hayakawa","year":"2020","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.phrs.2025.108066_bib79","doi-asserted-by":"crossref","unstructured":"G. Ursula, M. Aleksandra, I. Lucy, et al., Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non-Small Cell Lung Cancer with PIK3CA\/PTEN Alterations, 30 (18) (2024). https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-2540.","DOI":"10.1158\/1078-0432.CCR-23-2540"},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib80","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12943-021-01307-9","article-title":"Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer","volume":"20","author":"Wu","year":"2021","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.phrs.2025.108066_bib81","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41419-021-03844-z","article-title":"Targeting STAT3 signaling overcomes gefitinib resistance in non-small cell lung cancer","volume":"12","author":"Liu","year":"2021","journal-title":"Cell death Dis."},{"key":"10.1016\/j.phrs.2025.108066_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216205","article-title":"Reprogramming of TAMs via the STAT3\/CD47-SIRP\u03b1 axis promotes acquired resistance to EGFR-TKIs in lung cancer","volume":"564","author":"Lu","year":"2023","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.phrs.2025.108066_bib83","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.21037\/tlcr-23-99","article-title":"CDK4\/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer","volume":"12","author":"Hara","year":"2023","journal-title":"Transl. lung Cancer Res."},{"issue":"11","key":"10.1016\/j.phrs.2025.108066_bib84","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1002\/cncr.32809","article-title":"Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer","volume":"126","author":"Lee","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib85","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12964-023-01260-8","article-title":"Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer","volume":"22","author":"Ding","year":"2024","journal-title":"Cell communication signaling CCS"},{"issue":"11","key":"10.1016\/j.phrs.2025.108066_bib86","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1158\/1078-0432.CCR-19-3563","article-title":"Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-Mutant Lung Cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.phrs.2025.108066_bib87","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","article-title":"Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes","volume":"14","author":"Offin","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.phrs.2025.108066_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1004978","article-title":"The magic bullet: Niclosamide","volume":"12","author":"Jiang","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-023-01166-0","article-title":"Antibody-Drug Conjugates in Gynecologic Cancers","volume":"25","author":"Anastasio","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"issue":"6","key":"10.1016\/j.phrs.2025.108066_bib90","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s40262-017-0619-0","article-title":"Antibody-drug conjugates: pharmacokinetic\/pharmacodynamic modeling, preclinical characterization, clinical studies, and lessons learned","volume":"57","author":"Hedrich","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2025.108066_bib91","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/978-3-030-76912-3_15","article-title":"Importance and monitoring of therapeutic immunoglobulin G Glycosylation","volume":"112","author":"Mimura","year":"2021","journal-title":"Experientia supplementum (2012)"},{"issue":"3","key":"10.1016\/j.phrs.2025.108066_bib92","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/cei.13545","article-title":"Isotype selection for antibody-based cancer therapy","volume":"203","author":"Vukovic","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.phrs.2025.108066_bib93","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-1-0716-1944-5_13","article-title":"Engineering IgG1 Fc Domains That Activate the Complement System","volume":"2421","author":"Lee","year":"2022","journal-title":"Methods Mol. Biol. (Clifton N. J. )"},{"issue":"20","key":"10.1016\/j.phrs.2025.108066_bib94","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25204764","article-title":"Antibody-drug conjugates for cancer therapy","volume":"25","author":"Hafeez","year":"2020","journal-title":"Molecules"},{"issue":"15","key":"10.1016\/j.phrs.2025.108066_bib95","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1002\/anie.201307628","article-title":"Antibody-drug conjugates: an emerging concept in cancer therapy","volume":"53","author":"Chari","year":"2014","journal-title":"Angew. Chem. (Int. Ed. Engl. )"},{"issue":"20","key":"10.1016\/j.phrs.2025.108066_bib96","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clinical cancer research official journal American Association Cancer Research"},{"issue":"10","key":"10.1016\/j.phrs.2025.108066_bib97","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3253","article-title":"Microtubule-binding agents: a dynamic field of cancer therapeutics","volume":"9","author":"Dumontet","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10200","key":"10.1016\/j.phrs.2025.108066_bib98","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.108066_bib99","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.pharmthera.2016.07.012","article-title":"Antibody-drug conjugates: Current status and future perspectives","volume":"167","author":"G\u00e9bleux","year":"2016","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"issue":"12","key":"10.1016\/j.phrs.2025.108066_bib101","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody-drug conjugates: Recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.phrs.2025.108066_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2020.122075","article-title":"UPLC-based assay to assess the hydrophobicity of Antibody-Drug Conjugate (ADC) payloads","volume":"1146","author":"Pysz","year":"2020","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. life Sci."},{"issue":"11","key":"10.1016\/j.phrs.2025.108066_bib103","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119674","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"24","author":"Khoury","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.phrs.2025.108066_bib104","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1007\/s11095-015-1624-3","article-title":"Evolving strategies for target selection for antibody-drug conjugates","volume":"32","author":"Damelin","year":"2015","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.phrs.2025.108066_bib105","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/sj.leu.2403205","article-title":"Internalization and cell cycle-dependent killing of leukemic cells by gemtuzumab ozogamicin: rationale for efficacy in cd33-negative malignancies with endocytic capacity","volume":"18","author":"Jedema","year":"2004","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.phrs.2025.108066_bib106","doi-asserted-by":"crossref","first-page":"10540","DOI":"10.1074\/jbc.M510026200","article-title":"Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates","volume":"281","author":"Sutherland","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib107","first-page":"20","article-title":"Fate of Antibody-Drug Conjugates in Cancer Cells","volume":"37","author":"Chalouni","year":"2018","journal-title":"Journal experimental clinical cancer research CR"},{"key":"10.1016\/j.phrs.2025.108066_bib108","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.2147\/DDDT.S135571","article-title":"Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates","volume":"11","author":"Kalim","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2025.108066_bib109","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1158\/1535-7163.MCT-11-0727","article-title":"The effect of different linkers on target cell catabolism and pharmacokinetics\/pharmacodynamics of trastuzumab maytansinoid conjugates","volume":"11","author":"Erickson","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"18","key":"10.1016\/j.phrs.2025.108066_bib110","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1158\/1078-0432.CCR-19-0272","article-title":"Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index","volume":"25","author":"Coats","year":"2019","journal-title":"Clinical cancer research official journal American Association Cancer Research"},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib111","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1841393","article-title":"Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death","volume":"9","author":"Gomes-da-Silva","year":"2020","journal-title":"Oncoimmunology"},{"issue":"7","key":"10.1016\/j.phrs.2025.108066_bib112","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jamaoncol.2022.0503","article-title":"Evaluation of safety of treatment with anti-epidermal growth factor receptor antibody drug conjugate mrg003 in patients with advanced solid tumors: a phase 1 nonrandomized clinical trial","volume":"8","author":"Qiu","year":"2022","journal-title":"JAMA Oncol."},{"issue":"8_ement_2","key":"10.1016\/j.phrs.2025.108066_bib113","article-title":"Abstract CT008: First-in-human study of SYS6010, a novel EGFR targeting antibody drug conjugate (ADC) for patients with advanced solid tumors","volume":"85","author":"Lu","year":"2025","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.phrs.2025.108066_bib114","article-title":"Trastuzumab-emtansine and osimertinib combination therapy to target HER2 bypass track resistance in EGFR Mutation-Positive NSCLC","volume":"4","author":"Jebbink","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.phrs.2025.108066_bib115","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2021.11.021","article-title":"Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations","volume":"162","author":"Iwama","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2025.108066_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2021.01.248","article-title":"MA11.03 trastuzumab deruxtecan in her2-mutated metastatic non-small cell lung cancer (NSCLC): interim results of destiny-lung01","volume":"16","author":"Smit","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2025.108066_bib117","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2025.108066_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101795","article-title":"Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis","volume":"55","author":"Fu","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib119","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41392-024-01897-y","article-title":"SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1\/2 study","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"5","key":"10.1016\/j.phrs.2025.108066_bib120","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.annonc.2024.02.003","article-title":"Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC","volume":"35","author":"Yu","year":"2024","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib121","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, egfr-mutated non-small cell lung cancer","volume":"12","author":"J\u00e4nne","year":"2022","journal-title":"Cancer Discov."},{"issue":"35","key":"10.1016\/j.phrs.2025.108066_bib122","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"16_","key":"10.1016\/j.phrs.2025.108066_bib123","doi-asserted-by":"crossref","first-page":"9016","DOI":"10.1200\/JCO.2022.40.16_suppl.9016","article-title":"Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met\u2013overexpressing (OE) advanced non-small cell lung cancer (NSCLC)","volume":"40","author":"Camidge","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"16_","key":"10.1016\/j.phrs.2025.108066_bib124","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1200\/JCO.2022.40.16_suppl.9013","article-title":"Phase 1\/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC)","volume":"40","author":"Goldman","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.phrs.2025.108066_bib125","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab Vedotin monotherapy in patients with previously treated c-met protein-overexpressing advanced nonsquamous egfr-wildtype non-small cell lung cancer in the phase II LUMINOSITY Trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"29","key":"10.1016\/j.phrs.2025.108066_bib126","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1200\/JCO.23.00059","article-title":"First-in-human, phase i dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: tropion-pantumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.phrs.2025.108066_bib127","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1200\/JCO.2016.72.1894","article-title":"Therapy of advanced non-small-cell lung cancer with an sn-38-anti-trop-2 drug conjugate, sacituzumab govitecan","volume":"35","author":"Heist","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2025.108066_bib128","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03638-2","article-title":"Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1\/2 and phase 2 trials","author":"Zhao","year":"2025","journal-title":"Nat. Med."},{"issue":"0","key":"10.1016\/j.phrs.2025.108066_bib129","article-title":"Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial","volume":"389","author":"Wenfeng","year":"2025","journal-title":"BMJ"},{"issue":"23","key":"10.1016\/j.phrs.2025.108066_bib130","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-19-1133","article-title":"Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed\/refractory small-cell lung cancer: results from the phase ii trinity study","volume":"25","author":"Morgensztern","year":"2019","journal-title":"Clinical cancer research official journal American Association Cancer Research"},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib131","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","article-title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer","volume":"16","author":"Rudin","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib132","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.phrs.2025.108066_bib133","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.jtho.2021.03.012","article-title":"Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study","volume":"16","author":"Johnson","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.phrs.2025.108066_bib134","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","article-title":"Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study","volume":"16","author":"Blackhall","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib135","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/1078-0432.CCR-18-1590","article-title":"Trastuzumab Emtansine (T-DM1) in Patients with previously treated HER2-overexpressing metastatic non-small cell lung cancer: efficacy, safety, and biomarkers","volume":"25","author":"Peters","year":"2019","journal-title":"Clinical cancer research official journal American Association Cancer Research"},{"key":"10.1016\/j.phrs.2025.108066_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107385","article-title":"Management of HER2 alterations in non-small cell lung cancer - The past, present, and future","volume":"186","author":"N\u00fctzinger","year":"2023","journal-title":"Lung cancer (Amsterdam Netherlands)"},{"key":"10.1016\/j.phrs.2025.108066_bib137","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.lungcan.2020.11.004","article-title":"HER2 amplification as a potential mechanism of acquired resistance to afatinib in an advanced non-small-cell lung cancer patient","volume":"151","author":"Wang","year":"2021","journal-title":"Lung cancer (Amsterdam Netherlands)"},{"issue":"5","key":"10.1016\/j.phrs.2025.108066_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100260","article-title":"Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? an updated review on therapeutic strategies in NSCLC harbouring HER2 alterations","volume":"6","author":"Riudavets","year":"2021","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib139","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/1759-7714.14743","article-title":"Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer","volume":"14","author":"Zhang","year":"2023","journal-title":"Thorac. Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2025.108066_bib140","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013144","article-title":"Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models","volume":"13","author":"Marrocco","year":"2021","journal-title":"EMBO Mol. Med."},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib141","first-page":"174","article-title":"Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines","volume":"36","author":"La Monica","year":"2017","journal-title":"Journal experimental clinical cancer research CR"},{"issue":"9","key":"10.1016\/j.phrs.2025.108066_bib142","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.3390\/ijms22094774","article-title":"Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors","volume":"22","author":"Indini","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2025.108066_bib143","article-title":"Fam-Trastuzumab-Deruxtecan and Osimertinib Combination to Target HER2 driven resistance in a patient with NSCLC after osimertinib progression: case report","volume":"6","author":"Hirata","year":"2025","journal-title":"JTO Clin. Res. Rep."},{"issue":"31","key":"10.1016\/j.phrs.2025.108066_bib144","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients With HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 Trial","volume":"41","author":"Goto","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib145","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/0008-5472.CAN-21-2426","article-title":"EGFR Inhibition enhances the cellular uptake and antitumor-activity of the HER3 antibody-drug conjugate HER3-DXd","volume":"82","author":"Haikala","year":"2022","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib146","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12935-022-02844-z","article-title":"Changes in HER3 expression profiles between primary and recurrent gynecological cancers","volume":"23","author":"Kojima","year":"2023","journal-title":"Cancer Cell Int"},{"issue":"15","key":"10.1016\/j.phrs.2025.108066_bib147","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2217\/fon-2023-0602","article-title":"HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI","volume":"20","author":"Mok","year":"2024","journal-title":"Future Oncol. (Lond. Engl. )"},{"issue":"8","key":"10.1016\/j.phrs.2025.108066_bib148","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/10408363.2019.1653821","article-title":"HGF\/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers","volume":"56","author":"Moosavi","year":"2019","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"issue":"28","key":"10.1016\/j.phrs.2025.108066_bib149","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1038\/s41388-021-01863-w","article-title":"HGF\/c-MET pathway in cancer: from molecular characterization to clinical evidence","volume":"40","author":"Fu","year":"2021","journal-title":"Oncogene"},{"issue":"5827","key":"10.1016\/j.phrs.2025.108066_bib150","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science (New York N. Y. )"},{"issue":"2","key":"10.1016\/j.phrs.2025.108066_bib151","article-title":"Targeting MET in NSCLC: an ever-expanding territory","volume":"5","author":"Han","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"issue":"11","key":"10.1016\/j.phrs.2025.108066_bib152","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1111\/cas.14180","article-title":"SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met","volume":"110","author":"Tong","year":"2019","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.phrs.2025.108066_bib153","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ijc.2910620419","article-title":"The epithelial\/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7-3G11, is phosphorylated on serine 303","volume":"62","author":"Basu","year":"1995","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2025.108066_bib154","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/1476-4598-9-253","article-title":"Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway","volume":"9","author":"Cubas","year":"2010","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.phrs.2025.108066_bib155","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1634\/theoncologist.2013-0333","article-title":"The role of the PTEN\/PI3K\/Akt pathway on prognosis in epithelial ovarian cancer: a meta-analysis","volume":"19","author":"Cai","year":"2014","journal-title":"oncologist"},{"issue":"9","key":"10.1016\/j.phrs.2025.108066_bib156","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s00432-021-03784-3","article-title":"Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments","volume":"148","author":"Omori","year":"2022","journal-title":"J. Cancer Res Clin. Oncol."},{"issue":"3, ement","key":"10.1016\/j.phrs.2025.108066_bib157","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.jtho.2021.01.280","article-title":"OA03.03 datopotamab deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: updated results of tropion-pantumor01 phase 1 study","volume":"16","author":"Spira","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.phrs.2025.108066_bib158","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.2147\/DDDT.S489234","article-title":"Current status and future prospects of TROP-2 ADCs in lung cancer treatment","volume":"18","author":"Li","year":"2024","journal-title":"Drug Des. Dev. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2025.108066_bib159","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/hmg\/ddq529","article-title":"Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis","volume":"20","author":"Chapman","year":"2011","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"10.1016\/j.phrs.2025.108066_bib160","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1158\/0008-5472.CAN-08-2762","article-title":"Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer","volume":"69","author":"Jiang","year":"2009","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.phrs.2025.108066_bib161","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1083\/jcb.200702009","article-title":"Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivo","volume":"178","author":"Geffers","year":"2007","journal-title":"J. Cell Biol."},{"issue":"21","key":"10.1016\/j.phrs.2025.108066_bib162","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer: a review","volume":"333","author":"Kim","year":"2025","journal-title":"Jama"},{"key":"10.1016\/j.phrs.2025.108066_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115065","article-title":"Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy","volume":"213","author":"Saalfeld","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib164","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1186\/s12967-024-05568-y","article-title":"DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models","volume":"22","author":"Lin","year":"2024","journal-title":"J. Transl. Med."},{"issue":"10","key":"10.1016\/j.phrs.2025.108066_bib165","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1158\/1535-7163.MCT-23-0701","article-title":"FZ-AD005, a Novel DLL3-targeted antibody-drug conjugate with topoisomerase i inhibitor, shows potent antitumor activity in preclinical models","volume":"23","author":"Guo","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2025.108066_bib166","doi-asserted-by":"crossref","first-page":"750","DOI":"10.18632\/oncotarget.28660","article-title":"Relationship between the expressions of DLL3, ASC1, TTF-1 and Ki-67: first steps of precision medicine at SCLC","volume":"15","author":"Silva","year":"2024","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib167","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.phrs.2025.108066_bib168","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol."},{"issue":"7_ement","key":"10.1016\/j.phrs.2025.108066_bib169","article-title":"Abstract 5736: AZD9592: An EGFR-cMET bispecific antibody-drug conjugate (ADC) targeting key oncogenic drivers in non-small-cell lung cancer (NSCLC) and beyond","volume":"83","author":"Comer","year":"2023","journal-title":"Cancer Res."},{"issue":"7_ement","key":"10.1016\/j.phrs.2025.108066_bib170","article-title":"Abstract 5737: Evaluation of the relationship between target expression and in vivo anti-tumor efficacy of AZD9592, an EGFR\/c-MET targeted bispecific antibody drug conjugate","volume":"83","author":"McGrath","year":"2023","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.phrs.2025.108066_bib171","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1200\/JCO.23.00013","article-title":"Antibody-drug conjugates in lung cancer: recent advances and implementing strategies","volume":"41","author":"Passaro","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.phrs.2025.108066_bib172","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/JCO.2018.77.9777","article-title":"Ado-trastuzumab emtansine for patients With HER2-mutant lung cancers: results from a phase ii basket trial","volume":"36","author":"Li","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.phrs.2025.108066_bib173","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1200\/JCO.2018.78.7697","article-title":"First-in-Human Phase I, dose-escalation and -expansion study of telisotuzumab vedotin, an antibody-drug conjugate targeting c-met, in patients with advanced solid tumors","volume":"36","author":"Strickler","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2025.108066_bib174","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cllc.2020.09.013","article-title":"A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753)","volume":"22","author":"Waqar","year":"2021","journal-title":"Clin. lung Cancer"},{"issue":"24","key":"10.1016\/j.phrs.2025.108066_bib175","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab Govitecan Versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 Study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"16_","key":"10.1016\/j.phrs.2025.108066_bib176","article-title":"SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: Efficacy and safety data from a phase 2 study","volume":"41","author":"Fang","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.phrs.2025.108066_bib177","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab deruxtecan, a novel trop2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"16","key":"10.1016\/j.phrs.2025.108066_bib178","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1158\/1078-0432.CCR-20-3757","article-title":"First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors","volume":"27","author":"Maitland","year":"2021","journal-title":"Clinical cancer research official journal American Association Cancer Research"},{"issue":"16","key":"10.1016\/j.phrs.2025.108066_bib179","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.19.02085","article-title":"First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors","volume":"38","author":"Hassan","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2025.108066_bib180","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-13-2440","article-title":"An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors","volume":"74","author":"Breij","year":"2014","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.phrs.2025.108066_bib181","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.1016\/j.jtho.2019.08.414","article-title":"OA02.05 First-In-Human Phase 1\/2 Trial of Anti-AXL Antibody-2013;Drug Conjugate (ADC) Enapotamab Vedotin (EnaV) in Advanced NSCLC","volume":"14","author":"Ramalingam","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2025.108066_bib182","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/S1556-0864(23)00267-8","article-title":"13MO Safety and efficacy of tusamitamab ravtansine in combination with pembrolizumab \u00b1; chemotherapy in patients with CEACAM5-positive nonsquamous NSCLC (CARMEN-LC05 phase II study)","volume":"18","author":"Isambert","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib183","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","article-title":"The advantages of targeted protein degradation over inhibition: an rtk case study","volume":"25","author":"Burslem","year":"2018","journal-title":"Cell Chem. Biol."},{"issue":"12","key":"10.1016\/j.phrs.2025.108066_bib184","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.phrs.2025.108066_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127167","article-title":"Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide","volume":"30","author":"He","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2025.108066_bib186","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112061","article-title":"Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)","volume":"189","author":"Zhang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2025.108066_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113328","article-title":"Effective degradation of EGFR(L858R+T790M) mutant proteins by CRBN-based PROTACs through both proteosome and autophagy\/lysosome degradation systems","volume":"218","author":"Qu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"95","key":"10.1016\/j.phrs.2025.108066_bib188","doi-asserted-by":"crossref","first-page":"12852","DOI":"10.1039\/D1CC05715D","article-title":"Development of hypoxia-activated PROTAC exerting a more potent effect in tumor hypoxia than in normoxia","volume":"57","author":"Cheng","year":"2021","journal-title":"Chem. Commun. (Camb. Engl. )"},{"issue":"11","key":"10.1016\/j.phrs.2025.108066_bib189","doi-asserted-by":"crossref","first-page":"7839","DOI":"10.1021\/acs.jmedchem.1c00649","article-title":"Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP","volume":"64","author":"Zheng","year":"2021","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.phrs.2025.108066_bib190","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1042\/BST20180418","article-title":"PARPs in genome stability and signal transduction: implications for cancer therapy","volume":"46","author":"Palazzo","year":"2018","journal-title":"Biochem. Soc. Trans."},{"issue":"12","key":"10.1016\/j.phrs.2025.108066_bib191","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1016\/j.celrep.2019.05.058","article-title":"Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity","volume":"27","author":"Marcar","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.phrs.2025.108066_bib192","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.lungcan.2020.09.018","article-title":"Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)","volume":"150","author":"Garcia-Campelo","year":"2020","journal-title":"Lung cancer (Amsterdam Netherlands)"},{"key":"10.1016\/j.phrs.2025.108066_bib193","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113495","article-title":"Aurora kinase inhibitors as potential anticancer agents: Recent advances","volume":"221","author":"Pradhan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.phrs.2025.108066_bib194","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112803","article-title":"The oncogenic role of meiosis-specific Aurora kinase C in mitotic cells","volume":"407","author":"Bejar","year":"2021","journal-title":"Exp. Cell Res."},{"issue":"7","key":"10.1016\/j.phrs.2025.108066_bib195","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/13543776.2021.1890027","article-title":"Aurora kinase inhibitors: a patent review (2014-2020)","volume":"31","author":"Jing","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"issue":"15_","key":"10.1016\/j.phrs.2025.108066_bib196","article-title":"Phase I study of the aurora kinase A inhibitor alisertib in combination with osimertinib in EGFR-mutant lung cancer","volume":"39","author":"Blakely","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.phrs.2025.108066_bib197","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.ccell.2021.07.006","article-title":"Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis","volume":"39","author":"Tanaka","year":"2021","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.phrs.2025.108066_bib198","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s10637-020-01049-3","article-title":"Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors","volume":"39","author":"Quincy Siu-Chung","year":"2021","journal-title":"Investig. N. Drugs"},{"issue":"16_","key":"10.1016\/j.phrs.2025.108066_bib199","doi-asserted-by":"crossref","first-page":"8077","DOI":"10.1200\/JCO.2024.42.16_suppl.8077","article-title":"Phase I trial of aurora kinase A (AURKA) inhibitor VIC-1911 plus osimertinib for TKI-resistant, EGFR-mutant non-small cell lung cancer (NSCLC)","volume":"42","author":"Zhao","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"6487","key":"10.1016\/j.phrs.2025.108066_bib200","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw5473","article-title":"Metabolic reprogramming and cancer progression","volume":"368","author":"Faubert","year":"2020","journal-title":"Science (New York N. Y. )"},{"issue":"12","key":"10.1016\/j.phrs.2025.108066_bib201","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1002\/1878-0261.12814","article-title":"TRAP1 enhances Warburg metabolism through modulation of PFK1 expression\/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas","volume":"14","author":"Maddalena","year":"2020","journal-title":"Mol. Oncol."},{"issue":"11-12","key":"10.1016\/j.phrs.2025.108066_bib202","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s10495-022-01751-y","article-title":"The histone deacetylase SIRT6 promotes glycolysis through the HIF-1\u03b1\/HK2 signaling axis and induces erlotinib resistance in non-small cell lung cancer","volume":"27","author":"You","year":"2022","journal-title":"Apoptosis international journal programmed cell death"},{"issue":"30","key":"10.1016\/j.phrs.2025.108066_bib203","doi-asserted-by":"crossref","first-page":"20813","DOI":"10.1074\/jbc.M114.575464","article-title":"Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma","volume":"289","author":"Makinoshima","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.phrs.2025.108066_bib204","first-page":"9557","article-title":"EGF induces epithelial-mesenchymal transition and cancer stem-like cell properties in human oral cancer cells via promoting Warburg effect","volume":"8","author":"Qilin","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib205","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12672-025-01974-w","article-title":"Modulation of almonertinib resistance in non-small cell lung cancer by cancer-associated fibroblasts through HK2-mediated glycolysis and SKP2 signaling","volume":"16","author":"Wei","year":"2025","journal-title":"Discov. Oncol."},{"issue":"614","key":"10.1016\/j.phrs.2025.108066_bib206","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg6428","article-title":"Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"44","key":"10.1016\/j.phrs.2025.108066_bib207","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1038\/s41388-020-01480-z","article-title":"Multifaceted role of branched-chain amino acid metabolism in cancer","volume":"39","author":"Peng","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2025.108066_bib208","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106490","article-title":"Therapeutic targeting of glutamate dehydrogenase 1 that links metabolic reprogramming and Snail-mediated epithelial-mesenchymal transition in drug-resistant lung cancer","volume":"185","author":"Wang","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.phrs.2025.108066_bib209","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41392-024-01928-8","article-title":"Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.phrs.2025.108066_bib210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102724","article-title":"Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer","volume":"126","author":"Grant","year":"2024","journal-title":"Cancer Treat. Rev."},{"issue":"14","key":"10.1016\/j.phrs.2025.108066_bib211","doi-asserted-by":"crossref","first-page":"9662","DOI":"10.1021\/acs.jmedchem.2c00704","article-title":"Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer","volume":"65","author":"Eno","year":"2022","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.phrs.2025.108066_bib212","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2025.108066_bib213","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.actbio.2025.02.012","article-title":"Proteolysis-targeting chimera-doxorubicin conjugate nanoassemblies for dual treatment of EGFR-TKI sensitive and resistant non-small cell lung cancer","volume":"195","author":"Ma","year":"2025","journal-title":"Acta Biomater. 15"},{"issue":"4","key":"10.1016\/j.phrs.2025.108066_bib214","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1470-2045(25)00012-9","article-title":"Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study","volume":"26","author":"Li","year":"2025","journal-title":"Lancet Oncol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825004918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825004918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:38:06Z","timestamp":1778582286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825004918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":214,"alternative-id":["S1043661825004918"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.108066","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody-drug conjugates: A new twist to overcome EGFR-TKIs resistance in non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.108066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108066"}}